Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Gao, G. F. Natl. Sci. Rev. 8, nwab193 (2021).
Dai, L. & Gao, G. F. Nat. Rev. Immunol. 21, 73–82 (2021).
Xu, K., Dai, L. & Gao, G. F. Int. Immunol 33, 529–540 (2021).
Cao, Y. & Gao, G. F. EClinicalMedicine 32, 100746 (2021).
Sahin, U. et al. Nature 595, 572–577 (2021).
Zhang, N. N. et al. Cell 182, 1271–1283 (2020).
Huang, Q. et al. Nat. Commun. 12, 776 (2021).
Dai, L. et al. Cell 182, 722–733.e11 (2020).
An, Y. et al. Emerg. Microbes Infect. 11, 1058–1071 (2022).
Dai, L. et al. N. Engl. J. Med. 386, 2097–2111 (2022).
Vogel, A. B. et al. Nature 592, 283–289 (2021).
Zhao, X. et al. N. Engl. J. Med. 386, 894–896 (2022).
Xu, K. et al. Cell 185, 2265–2278.e14 (2022).
Huang, M. et al. Immunity 55, 1–14 (2022).
Fang, Z. et al. Nat. Commun. 13, 3250 (2022).
Acknowledgements
This work is supported by the National Key R&D Program of China (2020YFA0907100), the National Natural Science Foundation of China (NSFC) (82041048 and 81991494) and a grant from the Bill & Melinda Gates Foundation (INV-027420). L.D. is supported by the Excellent Young Scientist Program from NSFC (82122031) and the Chinese Academy of Sciences (YSBR-010). We thank Minrun Duan (Yunnan University), Tianyi Zheng (Zhejiang University), Sheng Liu (Southern University of Science and Technology) and Pei Du (Institute of Microbiology, CAS) for their assistance in the experiments and helpful suggestions. We thank Yuhai Bi, Ning Zhang, and all the staff of ABSL-3 at Institute of Microbiology, CAS for their assistance with the experiments performed in ABSL-3. We are grateful to Tong Zhao in Institute of Microbiology, CAS for her technical assistance with flow cytometry experiments.
Author information
Authors and Affiliations
Contributions
G.F.G., L.D., and Q.W. conceived and coordinated the project. Y.H., Y.A., Q.C., X.L., S.X., and H.D. conducted the experiments. A.B.V. and U.Ş. coordinated the comparison of the immunogenicity of RBD-dimer and RBD-trimer vaccines. K.X. and Y.H. wrote the manuscript. G.F.G., L.D., and Q.W. revised the manuscript.
Corresponding authors
Ethics declarations
Competing interests
Y.A., K.X., L.D, and G.F.G. are listed in the patent as the inventors of the prototype RBD-dimer as coronavirus vaccines. K.X., T.Z., L.D., and G.F.G. are listed in the patent as the inventors of chimeric Delta-Omicron RBD-dimer as coronavirus vaccine. U.Ş. is a management board member at BioNTech SE (Mainz, Germany) and U.Ş and A.B.V. are employees at BioNTech SE. A.B.V. and U.Ş. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccines having securities from BioNTech SE. All other authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Han, Y., An, Y., Chen, Q. et al. mRNA vaccines expressing homo-prototype/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2. Cell Res 32, 1022–1025 (2022). https://doi.org/10.1038/s41422-022-00720-z
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41422-022-00720-z
This article is cited by
-
An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants
npj Vaccines (2024)
-
Natural evidence of coronaviral 2′-O-methyltransferase activity affecting viral pathogenesis via improved substrate RNA binding
Signal Transduction and Targeted Therapy (2024)
-
Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines
Virology Journal (2023)
-
Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
Signal Transduction and Targeted Therapy (2023)
